Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.75 USD
0.00 (0.00%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 201 - 220 ( 393 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Telotristat NDA Accepted, Granted Priority Review, and PDUFA Set for 11/30; Reiterate OUTPERFORM but Raising PT to $30 for Reduced Regulatory Risk
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
June and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2016 Outlook: Lots of Cash, Major Catalysts and Reduced Risk; Reiterate OUTPERFORM and $28 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
May and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financial Update: 2016 Is Set to Be a Potential Value Creating Year; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
April and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
March and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY:15 Update; Several Potentially Material Catalysts in 2016; Reiterate OUTPERFORM and Raise PT to $28
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Results From Confirmatory Phase 3 Trial for Telotristat Etiprate Position Company for NDA Filing in Q1:16; Reiterate OUTPERFORM and $26 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Deal Resurrects T2DM for Sotagliflozin; Reiterate OUTPERFORM but Increasing Price Target to $26 for Increased Peak Sales Projection
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L